StocksExelixis IncEXEL

EXEL

Exelixis Inc

20.21 0.13 (0.66%)
Delayed Prices By NASDAQ, in USD Market Open
Trade
S
20.21
B
20.26

Overview

Prev Close20.08
Day's Range 19.87 - 20.31
52 Week Range 15.51 - 25.71
Average Volume (3m)2.23M
1-Year Return-20.03%
Beta0.8456
Market Cap6.43B
P/E Ratio28.06
Revenue1.43B
EPS0.7156
Dividend (Yield)0 (0%)
1 Day 1 Week 1 Month 3 Months 6 Months 1 Year 3 Years Max
Created with Highcharts 4.2.7 /Highstock 4.2.706/12/202115/02/202227/04/202216.0018.0020.0022.0024.00
Chart times in UTC
Industry Biotechnology
CEO Michael M. Morrissey, PhD
Employees 954

FINANCIAL SUMMARY

For the quarter ended 31/12/2021, Exelixis Inc's revenues increased by 37.37% and amounted to 451.14M. Net income increased by 149.10% to 95.17M. Net assets decreased by NaN to N/A and EPS increased from 0.12 to 0.29.
EXEL's Investor Relations
Income StatementBalance SheetCash Flow Statement
Quarterly
Gross Margin
96.32%
Net Profit Margin
35.08%
Operating Margin
19.98%
Return On Investment
28.32%
03/21
06/21
09/21
12/21
Total Revenue
270.23M
385.18M
328.42M
451.14M
Gross Profit
257.03M
370.29M
316.55M
438.22M
Operating Income
-4.61M
123.01M
51.62M
116.64M
Net Income
1.6M
96.09M
38.2M
95.17M